Geron Corporation Stock News

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted an equity award in the form of stock options to purchase 11,000,000 shares of common stock to Harout Semerjian, Geron's new President and Chief Executive Officer, as an inducement material to his acceptance of employment with Geron. The stock o...

Geron's Q2'25 sales of Rytelo (imetelstat) show clear growth, with net product revenue rising to $49M and underlying demand up 17%. Recent performance dispels fears that Rytelo's market share has already peaked, echoing past misjudgments seen with AUPH. A run-up into an interim readout from IMpactMF, GERN's trial of imetelstat in myelofibrosis, could begin in H1'26, since results are expected i...

Geron Corporation (NASDAQ:GERN ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants & - Corporate Participant David Borah - Corporate Participant Dawn Carter Bir - Interim President & Chief Executive Officer and Director Harout Semerjian - Corporate Participant James Ziegler - Executive VP & Chief Commercial Officer Joseph Emile Eid - Executive Vice President of Res...

Geron (GERN) Q2 Revenue Jumps 5,477%

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the second quarter of 2025 and recent business highlights. In a separate press release today, the Company announced the appointment of Harout Semerjian as incoming President and CE...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Harout Semerjian as President and Chief Executive Officer (CEO) and a member of the Board of Directors, effective tomorrow. Mr. Semerjian will succeed Dawn Carter Bir, who has served...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today announced that it will release its second quarter financial results and business highlights before the market opens on Wednesday, August 6, 2025 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference cal...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 342,000 shares of its common stock, consisting of stock options to purchase an aggregate of 228,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 114,000 shares o...